IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (15) , 2951-2963
Abstract
Previous studies have demonstrated that the antitumor potential of IU1 (a pharmacological compound), which was mediated by selective inhibition of proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14). However, the underlying molecular mechanisms remain elusive. It has been well established that mdm2 (Murine double minute 2) gene was amplified and/or overexpressed in a variety of human neoplasms, including cervical cancer. Furthermore, MDM2 is critical to cervical cancer development and progression. Relatively studies have reported that USP15 and USP7 stabilized MDM2 protein levels by removing its ubiquitin chain. In the current study, we studied the cell proliferation status after IU1 treatment and the USP14-MDM2 protein interaction in cervical cancer cells. This study experimentally revealed that IU1 treatment reduced MDM2 protein expression in HeLa cervical cancer cells, along with the activation of autophagy-lysosomal protein degradation and promotion of ubiquitin-proteasome system (UPS) function, thereby blocked G0/G1 to S phase transition, decreased cell growth and triggered cell apoptosis. Thus, these results indicate that IU1 treatment simultaneously targets two major intracellular protein degradation systems, ubiquitin-proteasome and autophagy-lysosome systems, which leads to MDM2 degradation and contributes to the antitumor effect of IU1.Keywords
This publication has 42 references indexed in Scilit:
- USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responsesNature Immunology, 2014
- Sorting out the trash: the spatial nature of eukaryotic protein quality controlCurrent Opinion in Cell Biology, 2014
- Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to ChemotherapyPLOS ONE, 2013
- Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1The EMBO Journal, 2011
- Ubiquitin-specific Cysteine Protease 2a (USP2a) Regulates the Stability of Aurora-AJournal of Biological Chemistry, 2011
- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARPJournal of Hematology & Oncology, 2011
- Enhancement of proteasome activity by a small-molecule inhibitor of USP14Nature, 2010
- Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cellsMolecular Cancer Therapeutics, 2009
- Regulation of the p14ARF-Mdm2-p53 pathway: An overview in breast cancerExperimental and Molecular Pathology, 2006
- Inhibiting the p53–MDM2 interaction: an important target for cancer therapyNature Reviews Cancer, 2003